Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | PRKACG | P22612 | 1/20 | 0.33 |
| ▸ | PRKACB | P22694 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 9/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.32 |
| ▸ | RAPGEF3 | O95398 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18720669 | 0.79 | RXFP1 (0.41) | RXFP1PRKACAPRKACGPRKACBPDE4A | |
| SCHEMBL18720750 | 0.77 | LMNA (0.41) | RXFP1STING1RAPGEF3LMNA | |
| SCHEMBL17826380 | 0.76 | PDE4A (0.40) | RXFP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18720720 | 0.74 | RXFP1 (0.54) | RXFP1STING1RAPGEF3LMNAGMNN | |
| SCHEMBL17304753 | 0.73 | STING1 (0.54) | RXFP1STING1RAPGEF3LMNAGMNN | |
| SCHEMBL18720717 | 0.73 | RXFP1 (0.49) | RXFP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18720658 | 0.72 | RXFP1 (0.36) | RXFP1PRKACAPRKACGPRKACBPDE4A | |
| SCHEMBL18720678 | 0.71 | RXFP1 (0.46) | RXFP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18720668 | 0.68 | STING1 (0.44) | RXFP1PRKACAPRKACGPRKACBPDE4A | |
| SCHEMBL18720718 | 0.68 | STING1 (0.53) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | TYMP, NSUN2, PNP | RXFP1 4795/4885PRKACA 1382/4885PRKACG 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.